P699 Impact of adalimumab's patient support program on clinical outcomes in inflammatory bowel diseases: results from the COMPANION study
Marshall J.K.*1,2, Narula N.1, Lebovic G.3,4, Millson B.5, Charland K.5, Sung M.5, Gaetano T.6, McHugh K.6, Latour M.6, Laliberte M.-C.6
1McMaster University, Department of Gastroenterology, Hamilton, Canada 2Farncombe Family Digestive Health Research Institute, Hamilton, Canada 3Applied Health Research Centre, St. Michael's Hospital, Toronto, Canada 4Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada 5QuintilesIMS, Kirkland, Canada 6AbbVie, St. Laurent, Canada
Adalimumab (ADL) is an anti-TNF biologic therapy indicated for the treatment of inflammatory bowel diseases (IBD), namely Crohn's disease (CD) and ulcerative colitis (UC). Patients receiving ADL in Canada are eligible to enroll in the AbbVie Care patient support program (PSP) which provides them with personalized services including ongoing care coach calls (CCC). In a previous study, IBD patients enrolled in Abbvie Care receiving CCC demonstrated significantly greater persistence and adherence to ADL than patients that did not receive CCC (no-CCC). The objective of this study is to compare the likelihood of achieving clinical remission in a cohort of IBD patients treated with ADL enrolled in the ADL PSP between those who received CCC versus those who did not receive CCC.
A longitudinal analysis using de-identified aggregate-level data collected through the AbbVie Care PSP was performed. Patients were indexed on the date of their first injection of ADL between January 2010 and October 2015. The ADL PSP database included patient measurements of the Harvey-Bradshaw Index (HBI), a measure of disease severity. To be eligible, patients had to have a baseline HBI measurement 90 days before to 30 days after their index date and have had a follow up HBI measurement 6 to 18 months later. HBI remission (HBI≤4) at the time of the follow up HBI assessment was compared in patients having received CCC and patients without CCC (no CCC). Robust Poisson regression was used to estimate the adjusted relative risk (RR) of HBI remission. Analyses were adjusted for patient age group, sex, region, prior biologic use, days lapsed between HBI assessments, and baseline disease severity category.
A total of 1469 IBD patients met eligibility criteria and 916 (62%) of these had received CCC. Of the 1469 patients, 1046 (71%) were in HBI remission at the second assessment, 682 (74%) in the CCC group and 364 (66%) in the group not receiving CCC. In the multivariable regression analysis, there was a 12% increased likelihood of achieving HBI remission in the CCC group relative to the group without CCC (RR=1.12, 95% confidence interval: 1.04, 1.20; p-value =0.002).
IBD patients receiving tailored services through the ADL PSP in the form of care coach calls have an increased likelihood of achieving HBI remission within 6 to 18 months. These results may help refine interventions aiming at improving clinical outcomes in IBD patients.